High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors
- 1Université Paris-Saclay, UVSQ, EA 4340 BECCOH, Boulogne-Billancourt, France
- 2Department of Medical Oncology, Centre Léon Bérard, Lyon, France
- 3Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France
- 4Department of Respiratory Diseases and Thoracic Oncology, APHP – Hopital Ambroise Pare, Boulogne-Billancourt, France
- 5Department of Pathology, APHP – Hopital Ambroise Pare, Boulogne-Billancourt, France
A Corrigendum on
High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors
By Takam Kamga P, Swalduz A, Costantini A, Julié C, Emile J-F, Pérol M, Avrillon V, Ortiz-Cuaran S, de Saintigny P and Giroux-Leprieur E (2021). Front. Oncol. 11:747692. doi: 10.3389/fonc.2021.747692
An author name was incorrectly spelled as Etienne Giroux LEPRIEUR. The correct spelling is Etienne GIROUX-LEPRIEUR.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR), Sonic Hedgehog (Shh), biomarker, tyrosine kinase inhibitor (TKI)
Citation: Takam Kamga P, Swalduz A, Costantini A, Julié C, Emile J-F, Pérol M, Avrillon V, Ortiz-Cuaran S, De Saintigny P and Giroux-Leprieur E (2022) Corrigendum: High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors. Front. Oncol. 12:852540. doi: 10.3389/fonc.2022.852540
Received: 11 January 2022; Accepted: 20 January 2022;
Published: 09 February 2022.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2022 Takam Kamga, Swalduz, Costantini, Julié, Emile, Pérol, Avrillon, Ortiz-Cuaran, De Saintigny and Giroux-Leprieur. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Etienne Giroux-Leprieur, Etienne.giroux-leprieur@aphp.fr